OncoMatch/Clinical Trials/NCT04541108
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies
Is NCT04541108 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including Rilvegostomig and Volrustomig for solid tumor.
Treatment: Rilvegostomig · Volrustomig · Sabestomig · Pembrolizumab — This is a multi-center, open-label Phase 0 Master Protocol designed to study the localized pharmacodynamics (PD) of anti-cancer therapies within the tumor microenvironment (TME) when administered intratumorally in microdose quantities via the CIVO device in patients with surface accessible solid tumors for which there is a scheduled surgical intervention. CIVO stands for Comparative In Vivo Oncology. Multiple substudies will include specified investigational agents and combinations to be evaluated.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UC Davis · Sacramento, California
- Emory Winship Cancer Institute · Atlanta, Georgia
- LSU Health Sciences Center - Shreveport · Shreveport, Louisiana
- Montefiore Medical Center · The Bronx, New York
- University of North Carolina · Chapel Hill, North Carolina
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify